Voyager Therapeutics (VYGR) FCF Margin (2015 - 2026)

Voyager Therapeutics has disclosed FCF Margin across 12 years of filings, most recently posting 1289.36% for Q1 2026.

• FCF Margin for Q1 2026 came in at 1289.36%, down 69623.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 355.36% (down 18527.0% YoY), and the FY2025 annual result was 334.53%, down 31099.0% from the prior year.
• FCF Margin came in at 1289.36% for Q1 2026 at Voyager Therapeutics, down from 200.92% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 5197.26% in Q1 2022 to a low of 2743.96% in Q2 2022.
• The 5-year median for FCF Margin is 114.6% (2024), against an average of 20.19%.
• Across the five-year window, FCF Margin surged 552508 bps in 2022 and sank 511549 bps in 2023, its largest moves.
• Voyager Therapeutics' FCF Margin stood at 850.13% in 2022, then plunged by 103 bps to 27.21% in 2023, then sank by 757 bps to 233.04% in 2024, then advanced by 14 bps to 200.92% in 2025, then sank by 542 bps to 1289.36% in 2026.
• The last three FCF Margin figures came in at 1289.36% (Q1 2026), 200.92% (Q4 2025), and 233.25% (Q3 2025), per Business Quant data.